FGF-HE001-100μg / 询价
FGF-HE001-500μg / 询价
FGF-HE001-500μgx2 / 询价
Human FGF basic Protein
Recombinant Human FGF basic Protein is expressed from E.coli without tag It contains Pro143-Ser288 [Accession | P09038-4].
The protein has a predicted MW of 16.5 kDa same as Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
Less than 0.02 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human FGF basic on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Human FGF basic at 0.5 μg/ml (100 μl/Well) on the plate. Dose response curve for Human Glypican 1, His Tag with the EC50 of 12.6 ng/ml determined by ELISA (QC Test).
Immobilized Human FGF basic, No Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Human FGFR2 beta (IIIc), His Tag with the EC50 of 1.18 μg/ml determined by ELISA.
Measured in a cell proliferation assay using BALB/c 3T3 mouse embryonic fibroblasts. The ED50 for this effect is 0.1 - 0.6 ng/ml (QC Test).
FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway.
bFGF; FGF basic; FGF2; FGF-2; FGF2AS; GFG1; HBGF-2; NUDT6; Prostatropin; BFGF; FGFB; FGFβ; HBGF2
(1) Zhiwu J , Xiaofeng J , Suimin C , et al. Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma[J]. Frontiers in Immunology, 2017, 7.
(2)Ho M , Kim H. Glypican-3: A new target for cancer immunotherapy[J]. European Journal of Cancer, 2011, 47(3):0-338.
